SOURCE: Caribbean International Holdings, Inc.

November 04, 2014 08:00 ET

New Management of CIHN Confirms Its First Stem Cell Patient and Treatment Being Performed by Dr. Liriano, With the Input of Dr. Gonzalez and Cells From Davinci Labs, CIHN Announces a Wide Variety of New Potential Patients to Come

OAKLAND PARK, FL--(Marketwired - November 04, 2014) - Caribbean International Holdings, Inc. (PINKSHEETS: CIHN) announces and confirms its first stem cell procedure to take place in Santiago, Dominican Republic, by Dr. Liriano with the input of Dr. Gonzalez. CIHN and its new management is excited to announce its first stem cell patient and treatment being performed at Dr. Liriano's facility This new patient is a 49-year-old male that is looking forward to his stem cell treatment in order to help improve overall wellness and minimize chronic back pain. Furthermore, this new patient and treatment is scheduled to take place on November 10th, 2014.

The new management of CIHN, along with Dr. Gonzalez has been in communication with a wide variety of new potential patients pursuing multiple different stem cell treatment options. CIHN is currently processing these potential patients' medical records and history in order to allow both Dr. Liriano and Dr. Gonzalez to determine treatments best suited for the individual. CIHN looks forward to working with and treating several of these potential patients in the near term and will keep the market updated in regards to its progress. The company appreciates the patience from its shareholders as it continues to create a presence in the rapidly emerging stem cell industry.

CIHN has scheduled a meeting with both Dr. Liriano and Dr. Gonzalez on November 11th, 2014 to go over the completed procedure and to discuss the future growth of CIHN. This includes outlining the future logistics and procedures to streamline future patients.

CIHN CEO, Mark Farber MD, PhD, MS received degrees from Brown University and SUNY; During his time at Harvard Medical School he developed bioreactor designs for stem cell based tissue engineered heart valves.

About Caribbean International Holdings, Inc. (CIHN):

Caribbean International Holdings, Inc. is a holding company for Regenerative Bio Science, Inc. ("RBSI"). The Company subsidiary RBSI is focused on helping individuals protect and ensure their future quality of life through Adult and/or Cord Blood Stem Cell Incubation and the practice of regenerative medicine in the United States and the Dominican Republic. RBSI's mission is not only to allow patients to store their Stem Cells for future use, but also perform patient funded stem cell therapies from sports injuries to degenerative diseases such as MS, Arthritis, Degenerative Heart Diseases, Diabetes and a host of experimental therapies in the brain trauma disease sector including CTE. The goal is to become a global leader in establishing protocols that can be patented and utilized to heal patients around the world.

Stem cells work as the repairmen of the body by replenishing and regenerating damaged tissues and cells. Certain conditions have shown marked improvement when treated with stem cells taken from the patient's own body as well as Cord Blood stem cells. Regenerative Bioscience is becoming part of a revolution in healthcare using stem cells.

Forward-Looking Statements Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "future," "plan" or "planned," "expects," or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and additional risks factors as discussed in reports filed by the company with the Securities and Exchange Commission, which are available on at

Contact Information